Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Sep;64(3):457–462. doi: 10.1038/bjc.1991.331

Human tumour-associated NK cells secrete increased amounts of interferon-gamma and interleukin-4.

J Lorenzen 1, C E Lewis 1, D McCracken 1, E Horak 1, M Greenall 1, J O McGee 1
PMCID: PMC1977624  PMID: 1911184

Abstract

Numerous interactions between malignant and stromal/inflammatory cells take place within solid human tumours, which are mediated, in part, by the release of signalling proteins called cytokines. In the present study, we have compared the secretion of two important immunomodulatory cytokines, IFN-gamma and IL-4 by individual, immunophenotyped NK cells freshly isolated from either malignant tumour biopsies, or peripheral blood samples from patients with ductal invasive breast cancer. Due to the marked heterogeneity amongst cells isolated from these clinical samples, we have employed a technique called the reverse haemolytic plaque assay to identify and enumerate cytokine-secreting cells at the single cell level. Our data indicate that NK cells isolated directly from the tumour site secrete more IFN-gamma and IL-4 than NK cells from the blood of the same patients. However, a greater proportion of CD16+ cells from both sources in breast cancer patients secreted IFN-gamma than of those from the blood of healthy donors. We also show that factors secreted by the human breast cell lines, MCF-7 and MDA-231 PN9, were able to mimic the stimulatory influence of the tumour microenvironment on secretory activity of NK cells.

Full text

PDF
457

Images in this article

459Figure 1
on p.459

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Al Jabaari B., Ladyman H. M., Larché M., Sivolapenko G. B., Epenetos A. A., Ritter M. A. Elevated expression of the interleukin 4 receptor in carcinoma: a target for immunotherapy? Br J Cancer. 1989 Jun;59(6):910–914. doi: 10.1038/bjc.1989.192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Andersson U., Andersson J., Lindfors A., Wagner K., Möller G., Heusser C. H. Simultaneous production of interleukin 2, interleukin 4 and interferon-gamma by activated human blood lymphocytes. Eur J Immunol. 1990 Jul;20(7):1591–1596. doi: 10.1002/eji.1830200727. [DOI] [PubMed] [Google Scholar]
  3. Chong A. S., Scuderi P., Grimes W. J., Hersh E. M. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor. J Immunol. 1989 Mar 15;142(6):2133–2139. [PubMed] [Google Scholar]
  4. Cordell J. L., Falini B., Erber W. N., Ghosh A. K., Abdulaziz Z., MacDonald S., Pulford K. A., Stein H., Mason D. Y. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984 Feb;32(2):219–229. doi: 10.1177/32.2.6198355. [DOI] [PubMed] [Google Scholar]
  5. Crawford R. M., Finbloom D. S., Ohara J., Paul W. E., Meltzer M. S. B cell stimulatory factor-1 (interleukin 4) activates macrophages for increased tumoricidal activity and expression of Ia antigens. J Immunol. 1987 Jul 1;139(1):135–141. [PubMed] [Google Scholar]
  6. Ellis T. M., McKenzie R. S., Simms P. E., Helfrich B. A., Fisher R. I. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma. J Immunol. 1989 Dec 15;143(12):4282–4286. [PubMed] [Google Scholar]
  7. Garcia-Peñarrubia P., Bankhurst A. D. Quantitation of effector-target affinity in the human NK cell and K562 tumor cell system. J Immunol Methods. 1989 Sep 1;122(2):177–184. doi: 10.1016/0022-1759(89)90262-7. [DOI] [PubMed] [Google Scholar]
  8. Giovarelli M., Santoni A., Jemma C., Musso T., Giuffrida A. M., Cavallo G., Landolfo S., Forni G. Obligatory role of IFN-gamma in induction of lymphokine-activated and T lymphocyte killer activity, but not in boosting of natural cytotoxicity. J Immunol. 1988 Oct 15;141(8):2831–2836. [PubMed] [Google Scholar]
  9. Guillou P. J., Sedman P. C., Ramsden C. W. Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro. Cancer Immunol Immunother. 1989;28(1):43–53. doi: 10.1007/BF00205800. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Handgretinger R., Kimmig A., Lang P., Daurer B., Kuci S., Bruchelt G., Treuner J., Niethammer D. Interferon-gamma upregulates the susceptibility of human neuroblastoma cells to interleukin-2-activated natural killer cells. Nat Immun Cell Growth Regul. 1989;8(4):189–196. [PubMed] [Google Scholar]
  11. Hart P. H., Vitti G. F., Burgess D. R., Whitty G. A., Piccoli D. S., Hamilton J. A. Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2. Proc Natl Acad Sci U S A. 1989 May;86(10):3803–3807. doi: 10.1073/pnas.86.10.3803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jabrane-Ferrat N., Calvo F., Faille A., Lagabrielle J. F., Boisson N., Quillet A., Fradelizi D. Recombinant gamma interferon provokes resistance of human breast cancer cells to spontaneous and IL-2 activated non-MHC restricted cytotoxicity. Br J Cancer. 1990 Apr;61(4):558–562. doi: 10.1038/bjc.1990.125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Julius M. H., Simpson E., Herzenberg L. A. A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur J Immunol. 1973 Oct;3(10):645–649. doi: 10.1002/eji.1830031011. [DOI] [PubMed] [Google Scholar]
  14. Kawakami Y., Rosenberg S. A., Lotze M. T. Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J Exp Med. 1988 Dec 1;168(6):2183–2191. doi: 10.1084/jem.168.6.2183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kelly P. M., Davison R. S., Bliss E., McGee J. O. Macrophages in human breast disease: a quantitative immunohistochemical study. Br J Cancer. 1988 Feb;57(2):174–177. doi: 10.1038/bjc.1988.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lanier L. L., Phillips J. H., Hackett J., Jr, Tutt M., Kumar V. Natural killer cells: definition of a cell type rather than a function. J Immunol. 1986 Nov 1;137(9):2735–2739. [PubMed] [Google Scholar]
  17. Leung K. H. Inhibition of human NK cell and LAK cell cytotoxicity and differentiation by PGE2. Cell Immunol. 1989 Oct 15;123(2):384–395. doi: 10.1016/0008-8749(89)90298-0. [DOI] [PubMed] [Google Scholar]
  18. Lewis C. E., McCarthy S. P., Richards P. S., Lorenzen J., Horak E., McGee J. O. Measurement of cytokine release by human cells. A quantitative analysis at the single cell level using the reverse haemolytic plaque assay. J Immunol Methods. 1990 Feb 20;127(1):51–59. doi: 10.1016/0022-1759(90)90340-2. [DOI] [PubMed] [Google Scholar]
  19. Lewis C. E., Ramshaw A. L., Lorenzen J., McGee J. O. Basic fibroblast growth factor and interleukins 4 and 6 stimulate the release of IFN-gamma by individual NK cells. Cell Immunol. 1991 Jan;132(1):158–167. doi: 10.1016/0008-8749(91)90015-4. [DOI] [PubMed] [Google Scholar]
  20. Lewis D. B., Prickett K. S., Larsen A., Grabstein K., Weaver M., Wilson C. B. Restricted production of interleukin 4 by activated human T cells. Proc Natl Acad Sci U S A. 1988 Dec;85(24):9743–9747. doi: 10.1073/pnas.85.24.9743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lotze M. T., Chang A. E., Seipp C. A., Simpson C., Vetto J. T., Rosenberg S. A. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA. 1986 Dec 12;256(22):3117–3124. [PubMed] [Google Scholar]
  22. Lotzová E. Ovarian-tumor-infiltrating lymphocytes: phenotype and antitumor activity. Nat Immun Cell Growth Regul. 1988;7(4):226–229. [PubMed] [Google Scholar]
  23. Luger T. A., Krutmann J., Kirnbauer R., Urbanski A., Schwarz T., Klappacher G., Köck A., Micksche M., Malejczyk J., Schauer E. IFN-beta 2/IL-6 augments the activity of human natural killer cells. J Immunol. 1989 Aug 15;143(4):1206–1209. [PubMed] [Google Scholar]
  24. Moy P. M., Holmes E. C., Golub S. H. Depression of natural killer cytotoxic activity in lymphocytes infiltrating human pulmonary tumors. Cancer Res. 1985 Jan;45(1):57–60. [PubMed] [Google Scholar]
  25. Mulé J. J., Smith C. A., Rosenberg S. A. Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells. J Exp Med. 1987 Sep 1;166(3):792–797. doi: 10.1084/jem.166.3.792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Mulé J. J., Yang J., Shu S., Rosenberg S. A. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. J Immunol. 1986 May 15;136(10):3899–3909. [PubMed] [Google Scholar]
  27. Mølvig J., Baek L., Christensen P., Manogue K. R., Vlassara H., Platz P., Nielsen L. S., Svejgaard A., Nerup J. Endotoxin-stimulated human monocyte secretion of interleukin 1, tumour necrosis factor alpha, and prostaglandin E2 shows stable interindividual differences. Scand J Immunol. 1988 Jun;27(6):705–716. doi: 10.1111/j.1365-3083.1988.tb02404.x. [DOI] [PubMed] [Google Scholar]
  28. Nagler A., Lanier L. L., Phillips J. H. The effects of IL-4 on human natural killer cells. A potent regulator of IL-2 activation and proliferation. J Immunol. 1988 Oct 1;141(7):2349–2351. [PubMed] [Google Scholar]
  29. Nakamura H., Ishiguro K., Mori T. Different immune functions of peripheral blood, regional lymph node, and tumor infiltrating lymphocytes in lung cancer patients. Cancer. 1988 Dec 15;62(12):2489–2497. doi: 10.1002/1097-0142(19881215)62:12<2489::aid-cncr2820621207>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  30. Neill J. D., Smith P. F., Luque E. H., Munoz de Toro M., Nagy G., Mulchahey J. J. Detection and measurement of hormone secretion from individual pituitary cells. Recent Prog Horm Res. 1987;43:175–229. doi: 10.1016/b978-0-12-571143-2.50011-3. [DOI] [PubMed] [Google Scholar]
  31. Ortaldo J. R., Mason A., Overton R. Lymphokine-activated killer cells. Analysis of progenitors and effectors. J Exp Med. 1986 Oct 1;164(4):1193–1205. doi: 10.1084/jem.164.4.1193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Packard B. S. Mitogenic stimulation of human tumor-infiltrating lymphocytes by secreted factor(s) from human tumor cell lines. Proc Natl Acad Sci U S A. 1990 Jun;87(11):4058–4062. doi: 10.1073/pnas.87.11.4058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Peleman R., Wu J., Fargeas C., Delespesse G. Recombinant interleukin 4 suppresses the production of interferon gamma by human mononuclear cells. J Exp Med. 1989 Nov 1;170(5):1751–1756. doi: 10.1084/jem.170.5.1751. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Peters P. M., Ortaldo J. R., Shalaby M. R., Svedersky L. P., Nedwin G. E., Bringman T. S., Hass P. E., Aggarwal B. B., Herberman R. B., Goeddel D. V. Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes. J Immunol. 1986 Oct 15;137(8):2592–2598. [PubMed] [Google Scholar]
  35. Procopio A. D., Allavena P., Ortaldo J. R. Noncytotoxic functions of natural killer (NK) cells: large granular lymphocytes (LGL) produce a B cell growth factor (BCGF). J Immunol. 1985 Nov;135(5):3264–3271. [PubMed] [Google Scholar]
  36. Rook A. H., Kehrl J. H., Wakefield L. M., Roberts A. B., Sporn M. B., Burlington D. B., Lane H. C., Fauci A. S. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol. 1986 May 15;136(10):3916–3920. [PubMed] [Google Scholar]
  37. Ruggiero V., Latham K., Baglioni C. Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells. J Immunol. 1987 Apr 15;138(8):2711–2717. [PubMed] [Google Scholar]
  38. Tamm I., Cardinale I., Krueger J., Murphy J. S., May L. T., Sehgal P. B. Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells. J Exp Med. 1989 Nov 1;170(5):1649–1669. doi: 10.1084/jem.170.5.1649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Tepper R. I., Pattengale P. K., Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 1989 May 5;57(3):503–512. doi: 10.1016/0092-8674(89)90925-2. [DOI] [PubMed] [Google Scholar]
  40. Uchida A., Vánky F., Klein E. Natural cytotoxicity of human blood lymphocytes and monocytes and their cytotoxic factors: effect of interferon on target cell susceptibility. J Natl Cancer Inst. 1985 Nov;75(5):849–857. doi: 10.1093/jnci/75.5.849. [DOI] [PubMed] [Google Scholar]
  41. Wahl S. M., Hunt D. A., Wong H. L., Dougherty S., McCartney-Francis N., Wahl L. M., Ellingsworth L., Schmidt J. A., Hall G., Roberts A. B. Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol. 1988 May 1;140(9):3026–3032. [PubMed] [Google Scholar]
  42. Wen D. R., Hoon D. S., Chang C., Cochran A. J. Variations in lymphokine generation by individual lymph nodes draining human malignant tumors. Cancer Immunol Immunother. 1989;30(5):277–282. doi: 10.1007/BF01744894. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Widmer M. B., Acres R. B., Sassenfeld H. M., Grabstein K. H. Regulation of cytolytic cell populations from human peripheral blood by B cell stimulatory factor 1 (interleukin 4). J Exp Med. 1987 Nov 1;166(5):1447–1455. doi: 10.1084/jem.166.5.1447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Young H. A., Ortaldo J. R. One-signal requirement for interferon-gamma production by human large granular lymphocytes. J Immunol. 1987 Aug 1;139(3):724–727. [PubMed] [Google Scholar]
  45. te Velde A. A., Klomp J. P., Yard B. A., de Vries J. E., Figdor C. G. Modulation of phenotypic and functional properties of human peripheral blood monocytes by IL-4. J Immunol. 1988 Mar 1;140(5):1548–1554. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES